WAT Q4 Deep Dive: Acquisition Integrates BD Biosciences, Margin Pressures Offset Revenue Growth

Scientific instruments company Waters Corporation (NYSE:WAT) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.8% year on year to $932.4 million. The company expects next quarter’s revenue to be around $1.20 billion, coming in 64.5% above analysts’ estimates. Its non-GAAP profit of $4.53 per share was in line with analysts’ consensus estimates.

Is now the time to buy WAT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Waters Corporation’s fourth quarter was met with a significant negative market reaction, with shares falling sharply. Management attributed the mixed market response primarily to unexpected weakness in the newly acquired BD Biosciences and Diagnostic Solutions business, as well as margin pressures from higher R&D investment and a shift to a subscription model for its Empower software. CEO Udit Batra acknowledged, “Several issues emerged in Q4 that impacted the growth of both of those businesses that were not fully known in Q3.” The company’s core business saw growth in recurring revenues, chemistry, and high single-digit gains in pharma and industrial end markets, but these positives were offset by underperformance in the acquired portfolio and declining operating margins.

Looking ahead, Waters Corporation’s guidance for the coming year is shaped by both cautious integration plans for the BD Biosciences and Diagnostic Solutions acquisition and anticipated benefits from enhanced pricing discipline, new product launches, and operational synergies. Management is focused on improving commercial execution, particularly through a centralized deal desk and expanding service plan attachment rates. CFO Amol Chaubal emphasized that guidance assumptions are prudent, stating, “We have risk-adjusted the underlying growth assumptions, even though most of the headwinds that impacted the business in 2025 are already in the baseline.” The company also expects gradual recovery in the acquired business and incremental recurring revenue as more customers adopt subscription models.

Key Insights from Management’s Remarks

Management explained that quarterly results were shaped by strong recurring revenue in core markets, new product launches, and the integration of BD Biosciences—though the latter introduced new headwinds.

• BD Acquisition Headwinds: The newly acquired BD Biosciences and Diagnostic Solutions business underperformed due to softer demand in China, delayed U.S. export approvals, and a milder flu season, resulting in a lower baseline for 2026 expectations.
• Subscription Model Transition: Waters’ transition of its Empower software from a traditional license to a subscription-based model created a short-term headwind for reported instrument revenue, but management emphasized the long-term benefit of higher-quality recurring revenue.
• Chemistry and Consumables Growth: Strong adoption of new chemistry products, including MaxPeak Premier technology and related bioseparation columns, drove double-digit growth in recurring consumables revenue, supported by price increases and new product launches.
• Operational Investments: Strategic acceleration of R&D investment—especially in informatics and bioseparations—was cited as a factor in lower operating margins, with management expecting these investments to yield growth in future periods.
• Pricing Discipline Initiatives: The company is applying centralized pricing and discount controls, particularly in acquired product lines, to improve margins and align pricing power across both legacy and acquired businesses.

Drivers of Future Performance

Waters expects steady organic growth driven by new product adoption, integration of BD Biosciences, and continued expansion into recurring revenue streams, but faces risks from integration execution and market headwinds.

• Integration and Synergy Realization: The success of Waters’ acquisition of BD Biosciences and Diagnostic Solutions will depend on swiftly realizing targeted cost and revenue synergies, including restructuring, procurement savings, and network optimization. Management expects $55 million in cost synergies and $50 million in revenue synergies in the coming year, with further upside if operational improvements materialize.
• Product Innovation and Recurring Revenue: Continued launches of new products in bioseparations, diagnostics, and informatics—especially the shift to subscription-based software—are expected to drive high-quality, recurring revenue growth. Management forecasts that recurring revenue will become a larger share of total revenue as subscription adoption increases.
• Market and Execution Risks: Persistent headwinds in China, variability in academic and government funding, and slower recovery in certain BD segments could limit near-term growth. Management highlighted that many of these risks are already incorporated in current guidance, but execution on integration, pricing, and commercial strategy remains critical.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) progress toward capturing cost and revenue synergies from the BD Biosciences integration, (2) the pace of customer adoption for subscription-based Empower software and related recurring revenue streams, and (3) stabilization and eventual recovery in the acquired business’s lagging segments, particularly in China and government markets. Continued product innovation and effective commercial execution will also be key areas of focus.

Waters Corporation currently trades at $319.44, down from $381.29 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.